Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70

Cancer Research

Volumn 67, Issue 20, 2007, Pages 10047-10057

  Chang, Chih Long ^a,b   Tsai, Ya Chea ^a   He, Liangmei ^a   Wu, T C ^a   Hung, Chien Fu ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; LUCIFERASE; PEPTIDE DERIVATIVE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LUMINESCENCE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; GREEN FLUORESCENT PROTEINS; HSP70 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 4; TRANSDUCTION, GENETIC;

EID: 35449003163     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0523     Document Type: Article

References (36)

1. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006;33: S12-6.
2. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107: 1399-410.
3. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 2006;33:S3-11.
4. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278:117-20.
5. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994;39:93-8.
6. Chen C-H, Suh KW, Ji H, Choti MA, Pardoll DM, Wu T-C. Antigen-specific immunotherapy for HPV-16 E7-expressing tumors grown in liver. J Hepatology 2000;33:91-8.
7. Singh-Jasuja H, Hilf N, Scherer HU, et al. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones 2000;5:462-70.
8. Spee P, Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 1997;27:2441-9.
9. Yamazaki K, Nguyen T, Podack ER. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol 1999;163:5178-82.
10. Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C. Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 2004;64: 1502-8.
11. Wang XY, Arnouk H, Chen X, Kazim L, Repasky EA, Subjeck JR. Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol 2006;177:1543-51.
12. + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21:4036-42.
13. Hauser H, Shen L, Gu QL, Krueger S, Chen SY. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 2004;11:924-32.
14. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
15. Hung CF, Tsai YC, He L, et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 2007;14:20-9.
16. Tseng JC, Levin B, Hurtado A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nature Biotechnol 2004;22:70-7.
17. Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nature Biotechnol 2004;22:589-94.
18. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
19. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007;25:127-35.
20. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42.
21. Hung CF, Tsai YC, He L, Wu TC. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther 2007;14:921-9.
22. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
23. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
24. Sanchez-Perez L, Kottke T, Daniels GA, et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 2006;177:4168-77.
25. Theriault JR, Mambula SS, Sawamura T, Stevenson MA, Calderwood SK. Extracellular Hsp70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett 2005;579: 1951-60.
26. Whittall T, Wang Y, Younson J, et al. Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur J Immunol 2006;36:2304-14.
27. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 2001;15:971-83.
28. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
29. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 2002;158:1277-85.
30. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002;169: 5424-32.
31. Li Z, Menoret A, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002;14:45-51.
32. Chen K, Lu J, Wang L, Gan YH. Mycobacterial heat shock protein 65 enhances antigen cross-presentation in dendritic cells independent of Toll-like receptor 4 signaling. J Leukoc Biol 2004;75:260-6.
33. Flohe SB, Bruggemann J, Lendemans S, et al. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 2003;170:2340-8.
34. Tseng JC, Hurtado A, Yee H, et al. Using Sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 2004;64:6684-92.
35. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003;20:733-44.
36. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 2005;22:674-84.